Objective: In many African Sub-Saharan countries, human papilloma virus (HPV) prevalence data are not available. The current study estimated the prevalence of HPV virus in the female population of Djibouti.
C ervical cancer represents the second cause of cancer for the female Djiboutian population by incidence (8.5 new cases per 100,000) and mortality (5.4 deaths per 100,000), after breast cancer. 1 The etiology of tumors of the uterine cervix is attributed to the persistent infection of cancerogenic types of human papillomavirus (HPV). 2, 3 Understanding the viral etiology has enabled new strategies of prevention to be put into place: the anti-HPV vaccine 4, 5 and the screening based on the test for the search for HPV DNA. 6 The HPV test is therefore gaining importance for the early diagnosis of tumors of the cervix, in association with or as an alternative to the Pap test. 7, 8 Also in countries with scarce resources, such as India, a large trial has reported that even a single HPV test in a lifetime can reduce the incidence of cervix cancer at an advanced stage and the associated mortality, when compared with no intervention, whereas a single Pap test or a single visual inspection with acetic acid (VIA) did not cause any significant reduction of the disease. 9 The knowledge of epidemiology of the HPV infection is therefore an important tool for planning and evaluating every strategy of prevention of cervical carcinoma. It offers a prevaccine framework to evaluate the impact of the vaccination and supplies the necessary information to assess the workload of a possible screening program.
In many Sub-Saharan countries, no data are available on the prevalence of HPV. 10 The present study, conducted through a project of international cooperation aimed at implementing programs of public health for the female population of Djibouti, has estimated the HPV virus prevalence in this population.
METHODS
The study was carried out for the project "Support to Djiboutian Programs for Womens' Health," conducted in collaboration with the Ministry of Health of Djibouti and the National Institute for Health, Migration and Poverty (INMP) and financed by the Italian Ministry of Foreign Affairs and Cooperation. The project lasted 2 years and, among its activities, provided for the enrollment of 998 women to undergo HPV testing using a probe for high-risk types (Hybrid Capture2 [HC2]-HPV-DNA, Qiagen, Hilden, Germany): 499 women were enrolled from March 24 to April 7, 2014, and 499 from March 1 to 18, 2015.
The criteria for inclusion were as follows: asymptomatic women 16 to 64 years old; with previous sexual relations; sexually inactive in the 2 days before the sampling; when pregnant, within the 34th week of pregnancy; during the menstrual cycle, between the 10th and 24th days.
The present prevalence study was based on the data collected during both years of the project. The women enrolled in the gynecology clinic of the National Reference Center for Reproductive Health (Housseina), the National Reference Center for Maternity (Dar El Hanan), and the Balbala Hospital.
During the 2 years of the project, 298 women (29.9%) were enrolled in the Housseina Center, 251 (25.2%) in the Balbala Hospital, and 449 (45.0%) in the Dar El Hannan Center.
After the radio/television advertising campaign carried out by the Ministry of Health of Djibouti, women attended the clinics for routine gynecological tests. Most women presented for enrollment exclusively to undergo the test for screening.
The research protocol was designed by INMP in collaboration with the Italian Screening Group for Cervical Cancer (GISCI) and shared with the Director of the Maternal and Child Health Department (Département de la Santé de la Mére et de l'Enfant), the administrators and gynecologists of the 3 centers involved, and the ethical board of the Djiboutian Ministry of Health, which approved it. Health cards and the forms for collecting the informed consent were handed to the patients at the time of HPV testing.
The cervical-vaginal cytology samples were carried out using a liquid transport medium (PreservCyt; Hologic, Inc, Marlborough, MA). The sampling is the same as that used for the traditional technique; however, the technician used a new brush (Cervex-Brush Combi; Hologic, Inc) to simultaneously collect both ectocervical and endocervical cells. The cellular material sampled was immersed in a liquid solution and stored under appropriate conditions, to permit performance of HPV test according to HC2 methodology and subsequent genotyping of the virus in the HPV-positive samples.
The samples were obtained by the midwives of the 3 Djiboutian health centers involved, who had already received training through theoretical/practical courses, organized and conducted by INMP for the project.
The Subsequently, the HPV-positive samples were set up in thin layers on cytological slides (ThinPrep; Hologic, Inc) for the Pap test reading. The cytology was reported according to the TBS2001 classification (NILM, LSIL, HSIL, AIS, carcinoma, ASC-US, ASC-H, AGC, and adenocarcinoma). 12 Finally, INMP provided the results of the analyses to the 3 centers in Djibouti for communication to the women enrolled in the study. When HPV positive, the patients were sent to the National Referral Center for the womens' health. According to protocol, the women with HPVpositive and abnormal Pap test would undergo a colposcopy for a colposcopic-guided biopsy, to confirm the presence of the lesion, whereas HPV-positive and cytology NILM women were invited for a new co-test after 1 year. For women with high-grade lesions (CIN2/CIN3), the protocol established conservative treatment, whereas for women with CIN1, based on the clinical characteristics of the lesion and the logistical difficulty of follow-up, the gynecologist would be able to decide to follow up in 6 to 12 months or carry out conservative treatment. The implementation and the results of the second level visit were not recorded, as they were not conducted within the study.
All the data relative to the person and the results of the HPV tests were collected in a deidentified database, in accordance with privacy regulations.
Statistical Analysis
We calculated crude and standardized HPV-positivity prevalence rates with 95% confidence intervals. The evaluation of the differences in the distribution of categorical variables was carried out using the chi-square test, and that of the discrete variables was done using the nonparametric Kruskal-Wallis test. To evaluate the factors associated with the probability of being HPV positive, we performed a multivariate logistic model, adjusting for age class, residence, education, marital status, and number of partners. Odds ratio and 95% confidence intervals were estimated.
RESULTS
Supplemental Digital Content 1, Table, http://links.lww.com/ LGT/A38, summarizes sociodemographic characteristics of the 998 women. The average age was 38.8 years (SD, 10.2), and median age was 38 years. Most of the women were married or had been married, except for 70 single women (7.0%). On average, the women had 3.6 children (SD, 3.1), with a median of 3 (Table 1) .
Fifty-four women tested HPV positive (5.4% of the 998 women), 11 (3.7%) in the Housseina Center, 14 (5.6%) from the Balbala Hospital, and 29 (6.5%) from the Dar El Hannan Center. No statistically significant difference was observed in the prevalence of HPV among the centers (P = 0.26). SDC Supplemental Digital Content 2, Figure, http://links.lww.com/LGT/A39 shows the HPV prevalence at each center.
Taking into consideration only the HPV types classified as group 1 by the IARC, the prevalence was 3.9% of the 998 women in the study (39 women) (Figure 1 ).
Supplemental Digital Content 3, Figure, http://links.lww. com/LGT/A40 shows the crude prevalence of HPV positive per age group. Among the women younger than 34 years, higher levels were observed: in particular among the women 30 to (Figure 2 ). Supplemental Digital Content 4, Table, http://links.lww.com/ LGT/A41 summarizes some of the characteristics of the women enrolled, according to the result of the HPV test. Women born in Djibouti city tested positive (6.4%), compared with those born in the countryside (4.4%) or those born overseas (4.3%). Nearly all the women who tested positive were city dwellers (n = 53). Married women had a 5.3% probability of being HPV-positive compared with previously married or unmarried (2.9%); the percentage of HPV-positive women was 10.9% among those with an unknown marital status. The women with a maximum of 3 children were 6.1% HPV-positive compared with those with 4 or more children (4.9%). The percentage of HPV-positive, among women who reported more than one partner, was more than double with respect to those who said they had only had one partner (11.6% vs 4.8%, P = 0.02) ( Table 2) .
Supplemental Digital Content 5, Table, http://links.lww.com/ LGT/A42 shows the results of genotyping of the HPV for the 54 positive women and prevalence among women with normal cytology. Sixty-five infections were isolated; in 11 of the 54 women (20.4% of the HPV-positive), multiple infections were identified (Table 3) .
HPV66 was the most frequent type representing 15.4% of the infections, followed by types HPV31 and HPV52 (10.8% each). In our sampling, type 16 made up 9.2% of the isolated types, whereas type 18 was 4.6%, and they were present in 16.7% of the 54 HPV-positive women.
In women who tested positive for HPV, the oncogenic types classified as "group 1" represented 64.6% of the overall types isolated and were present in 77.8% of the women; those classified as "group 2a" accounted for 4.6% of overall types and were present in 5.6% of the women, and the "group 2b" represented 24.6% of overall types and were present in 29.6% of women testing HPVpositive.
Of the 11 women who presented 2 different HPV types, type 66 was found in 3 women as a second genotype; type 53 in 2 women; and types 39, 52, 59, 68, 70, and 82 were each found in 1 woman.
The age group with the highest percentage of women positive for "group 1" HPV was 30 to 34 (8.6%), followed by the 16 to 24 year group (7.1%) and that of women older than 60 years (5.3%).
All 54 women who tested HPV-positive underwent a Pap test: abnormal in 8 (14.8%), with high-grade squamous intraepithelial lesions (HSIL) in 2 women, low-grade squamous intraepithelial lesions (LSIL) in 6 women, and normal in 46 women. Supplemental Digital Content 6, Table, http://links.lww.com/ LGT/A43 shows the results of the multivariate logistic model: the probability to be HPV-positive was significantly higher for the women who reported at least 2 sexual partners compared with those who reported only 1 partner (Table 4) .
DISCUSSION
Our study found a prevalence of HPV in Djibouti equal to 5.4% and 3.9% for the high-risk cancer types.
The prevalence of all HPV types among the 990 women of Djibouti with normal cytology was lower than that observed in Africa, Europe, and America. The only estimates of prevalence for the Horn of Africa concerned Ethiopia, 13 with a reported prevalence equal to 15.9% and 17.5%. 14, 15 The prevalence in this healthy population was lower than that in other NorthAfrican countries (Algeria, 16 Egypt, 17 Tunisia, 18 and Morocco 19 ), reported to be approximately 10% of the population are 18 to 60 years old, and lower than Sub-Saharan countries and Ethiopia, 14, 15 where prevalence exceeds 10% everywhere with peaks up to more than 50%. 10, 20 The prevalence curve according to age shows the typical U trend seen in African countries. This trend is different to that found in most parts of the rest of the world, where decreasing trends prevail. 13, 21 Among the types found in the healthy population of Djibouti, it should be noted that the proportion of HPV16 is among the lowest ever seen in similar studies. The data are even much lower than that seen in neighboring countries where, although the proportion of HPV16 in healthy women with HPV infection is among the lowest in the world, this type is still the most frequent. 10, 13 The data on type HPV66 were unexpected. In fact, the HPV66, a type included in group 2b, possible oncogenic according to IARC classification, 11 is not a direct target of the high-risk probe of the HC2 test. However, HPV66 DNA cross hybridizes with the probes for other phylogenetically similar types included in the mix for high-risk types. [22] [23] [24] The prevalence of HPV66 might therefore be underestimated. Notwithstanding, the proportion of HPV66 infections among healthy women in the Horn of Africa is the highest on the continent and double that of the world average. 10, 13 It is worth keeping in mind that data on the prevalence of HPV types circulating in the general population do not represent the proportion of viral types causing cancers. In fact, HPV types found in cancers depends mostly on the carcinogenic power of the virus, rather than on the mix of types circulating in the healthy population. 25 This is why the viral types most frequently found in cancers are almost the same worldwide. Nevertheless, the very low prevalence of HPV 16, the most cancerogenic HPV type, observed in our sample, may explain the relatively low incidence of cervical cancer in Djibouti, notwithstanding that the prevalence of HPV is not extremely low and given that screening is not very widespread.
We found a low rate of abnormal cytology among the highrisk HPV positive. These data may be due to a high specificity and low sensitivity, but the same center has more than 50% abnormal cytology in the screening of the Italian HPV-positive population. 26 This result is in agreement with the fact that circulating high-risk types are not as oncogenic as types 16 and 18.
Our results supply useful information for future screening programs. In Djibouti, the prevalence is sufficiently low that in the event of HPV screening, 27 the workload generated for colposcopy or VIA verification would not be very high. The prevalence of high-grade cytologic abnormalities was very low. An aggressive approach of direct treatment with cryotherapy for 27 would not be justified in Djibouti. A cytological triage, if feasible, would be able to significantly reduce the load of second level verification and make a treatment strategy without colposcopy-guided biopsy verification more acceptable.
The proposed strategy of screening in countries with scarce resources generally includes treatment or an immediate colposcopy or VIA for all HPV-positive women, according to WHO guidelines. 27 Moreover, very aggressive strategies are justified in countries where screening cannot be frequently repeated, and the follow-up of women can prove difficult. In these countries, a high prevalence of high-grade lesions have been observed among those testing positive for HPV, because of the fact that the population had never previously undergone screening, and therefore, there are many long-term infections with a high probability of underlying high-grade lesions. 13, 28 The main limitation of the study is the small number of samples and the small number of HPV-positive subjects, which forces us to take into account the range of variability in the evaluation of prevalence, which leaves room for considerable uncertainty.
Spontaneous enrollment is hardly representative of the population, but active invitation from data lists are not conceivable in this context and neither is active contact with a household, suggesting a cervical-vaginal sample could never be carried out in a random sample of women, in particular in a Muslim country. Another risk of spontaneous access enrollment, as in case of selection bias previously presented, is that a group of symptomatic women can increase the prevalence, a situation that cannot be excluded in our study. If this way of recruiting women may lead to distorted estimates of the prevalence in the population, it gives a more precise idea of the prevalence of HPV and Pap positive cases in a population undergoing screening, given that a mass screening program would follow similar enrollment strategies, at least initially. It must be taken into account that our typing strategy can only give reliable results about the prevalence of the group 1 types (16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, and 59) and on type 68 (group 2a) that are included in the HC2 probe. For the other types, we only have occasional findings because of the cross hybridization of HC2 probe with phylogenetically similar types of coinfections.
Finally, results of the colposcopy and the biopsies carried out in HPV and cytology positive women are not available and the follow-up results of women; this does not allow an estimation to be made on the risk of lesions in the potential population target of screening or the positive predictive value of a colposcopy with different screening algorithms. 
CONCLUSIONS
This study was able to assess, for the first time, the prevalence of women positive for the HPV virus in Djibouti. This is a baseline information to plan and evaluate any strategy of prevention for cervix cancer in the Djiboutian population. The low prevalence of HPV infections and the low prevalence of high-grade lesions observed within our study may offer Djibouti a choice of strategies including forms of cytological triage, thus limiting the demand for colposcopy and treatment. 29 
